The tissue is the issue: personalized medicine for non-small cell lung cancer

Clin Cancer Res. 2010 Oct 15;16(20):4909-11. doi: 10.1158/1078-0432.CCR-10-2005. Epub 2010 Oct 5.

Abstract

The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed.

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / metabolism
  • Molecular Targeted Therapy / methods*
  • Precision Medicine / methods*